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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S135real-time PCR. The phosphorylation of ERK was measured by ELISA. MKP-1
expression was measured by real-time PCR and western blotting.
Results: IL-6+sIL-6R, IL-1b and TNF-a inducedMMP-3 andADAMTS-4mRNA
in human articular chondrocytes in a concentration-dependent manner.
Moreover, all three cytokinespromoted thephosphorylation of ERK,whereas
the total amount of ERK did not change. Both HA and ERK inhibitor
completely inhibitedMMP-3 andADAMTS-4mRNA inductionby IL-6+sIL-6R
or IL-1b, but both did not inhibit MMP-3 and ADAMTS-4mRNA induction by
TNF-a. Both HA and ERK inhibitor completely suppressed the phosphoryla-
tion of ERK induced by all cytokines in human articular chondrocytes.
To further analyze the inhibitory action of HA on ERK signal pathways
induced by IL-6+sIL-6R and IL-1b, we tested whether HA could induce
MKP-1, a negative regulator of ERK. HA treatment induced the expression
of MKP-1 mRNA and its protein in human articular chondrocytes.
To determine the involvement of MKP-1 in HA-induced suppression of
MMP-3 and ADAMTS-4 expressions induced by IL-6+sIL-6R and IL-1b, we
examined whether MKP-1 inhibitor could block the effect of HA. MKP-1
inhibitor clearly reversed the suppressive effect of HA on MMP-3 and
ADAMTS-4 expressions induced by IL-6+sIL-6R and IL-1b.
Conclusions: Our study clearly demonstrates that ERK involves in the
induction of MMP-3 and ADAMTS-4 by IL-6+sIL-6R and IL-1b, but not by
TNF-a. HA suppresses the induction of MMP-3 and ADAMTS-4 via the
induction of MKP-1, a negative regulator of ERK.
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RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR-18 (RHFG18)
PROMOTES BOVINE ARTICULAR CHONDROCYTE PROLIFERATION AND
CARTILAGE MATRIX PRODUCTION IN VITRO.
A. Gigout, D. Werkmann, S. Lindemann, K. Kleinschmidt,
H. Guehring. Merck-Serono, Darmstadt, GERMANY
Purpose: An important goal in the treatment of patients with osteoar-
thritis and cartilage injury is to restore the articular surface of degraded or
injured cartilage. Regeneration could be achieved by anabolic compounds
stimulating extracellular matrix (ECM) molecule production and recellu-
larization, thereby compensating for the matrix and cell loss occurring in
OA cartilage. The present work sought to evaluate the ability of recombi-
nant human ﬁbroblast growth factor-18 (rhFGF18) to exhibit such prop-
erties in various in vitro and ex vivo systems.
Methods: Primary bovine articular chondrocytes were tested for expres-
sion of ﬁbroblast growth factor receptor 3 (FGFR3, the main receptor for
rhFGF18 signaling in cartilage) at the mRNA and protein level by quanti-
tative polymerase chain reaction (qPCR) and Western Blot, respectively. A
dose-response curve (0.1-10 000 ng/mL rhFGF18) was realized in mono-
layer to determine the best dosage. Next, 3D cultures with 10 and 100 ng/
mL rhFGF18 were performed with rhFGF18 applied for 4 weeks (4w), or for
1 week followed by 3 weeks without rhFGF18 (1w). Cell proliferation was
evaluated in monolayer using a cell counter. ECM production and the
chondrocytic phenotype were investigated for both monolayer and 3D
cultures by qPCR for collagen I, II, X, aggrecan and Sox9. Glycosamino-
glycan (GAG) content of the 3D constructs was also evaluated with the
dimethylmethylene blue assay after proteinase K digestion. Finally, the
impact of rhFGF18 (100 ng/mL) on proliferation in bovine cartilage
explants was assessed. For this purpose, cell counting using automated
image analysis was done after 41 days of culture with/without rhFGF18. In
a second trial, cell proliferation was quantiﬁed using proliferating cell
nuclear antigen (PCNA) staining in histological sections in bovine cartilage
explants after 0, 2, 4, 6 weeks' rhFGF18 administration.
Results: At both the protein and mRNA levels, primary bovine articular
chondrocytes expressed FGFR3. In monolayer cell culture they responded
to rhFGF18 with a dose-dependent increase in proliferation (1.9 fold at 10
ng/mL) and a dose-dependent decrease of collagen type I expression (64
fold at 100 ng/mL). In 3D culture (see Figure), short exposure to rhFGF18
100 ng/mL (1w) triggered GAG production (1.5 fold) and collagen type II
expression (3.2 fold), while collagen type I expression was decreased (2.3
fold). Chondrocyte proliferation was also stimulated in bovine cartilage
explants by 100 ng/mL rhFGF18, demonstrating its ability to reach the cells
in cartilage. The maximum effect of rhFGF18 on explants was observedafter 4 weeks in culture (11.25% PCNA positive cells with rhFGF18 treat-
ment compared to 4.88% PCNA positive cells without rhFGF18).Figure: GAG content and collagen (Col.) types I and II gene expression in 3D
constructs cultured in absence (CTR, control) or presence of rhFGF18 (100
ng/mL) over a 4-week culture period (4w) or for the ﬁrst week (1w) only.
Conclusions: Taken together these results suggest that rhFGF18 can efﬁ-
ciently penetrate cartilage, and stimulate chondrocyte proliferation and
cartilage ECM production. This is consistent with previous in vitro studies
and further strengthens the rationale for the current clinical investigation
of rhFGF18 as an anabolic disease modifying osteoarthritis drug (DMOAD).261
A UNIQUE TOOL TO SELECTIVELY DETECT THE CHONDROGENIC IIB
FORM OF HUMAN PROCOLLAGEN II PROTEIN.
E. Aubert-Foucher 1, M. Pasdeloup 1, N. Mayer 1, A. Pagnon 2,
D. Hartmann 3, F. Mallein-Gerin 1. 1Université Lyon 1, Univ Lyon, CNRS,
FRE 3310 - Dysfonctionnement de l'Homéostasie Tissulaire et Ingénierie
Thérapeutique, IBCP, F69367 Lyon, France; 2Novotec, 13-15 rue Jacques
Monod, F69007 Lyon, France; 3UCBL 1/ISPB, Faculté de Pharmacie, UMR
CNRS 5510/MATEIS, Equipe I2B -"Interactions Biologiques et Biomatériaux",
8 avenue Rockefeller, F69373 Lyon, Cedex 08, France
Purpose: Type II collagen, the major ﬁbrillar collagen of cartilage, is
synthesized in precursor forms (procollagens) containing NH2- and COOH-
terminal propeptides. Three splice variants are thought to be translated to
produce procollagen II isoforms (IIA/IID and IIB) that differ in their ami-
nopropeptide parts. The IIA and IID are transient embryonic isoforms
which include an additional cysteine rich domain implicated in the regu-
lation of TGF-b superfamily signalling. The IIA and IID transcripts are co-
expressed during chondrogenesis then decline and the IIB isoform is the
only one expressed and synthesized in mature fully differentiated chon-
drocytes. Besides, procollagen IIA can be re-expressed by dedifferentiating
chondrocytes and in osteoarthritic cartilage. Therefore, it is an important
point to determine which isoform(s) is (are) synthesized in vivo in normal
and pathological situations and in vitro, to complete the phenotypic
characterization of collagen II protein producing cells. Antibodies directed
against the cysteine rich extradomain of procollagen IIA are already
available and our goal in this study was to obtain and validate for the ﬁrst
time antibodies detecting only the chondrogenic IIB form of procollagen II.
Methods:Wedesigned a triple peptide anti-peptide strategy to produce, to
titer by ELISA and to afﬁnity-purify rabbit polyclonal antibodies to human
procollagen IIB. Human knee chondrocytes and the Saos-2 human osteo-
blastic cell line were cultured in various conditions to prepare cell extracts
and media for the analysis of ﬁbrillar procollagens synthesized and
recognized by our antibodies to procollagen IIB by Western-blotting (WB).
Results: The antibodies to procollagen IIB (now referred to as anti-pNIIB52
antibodies) show a strong reactivity in WB with procollagen II and with
pN-collagen IIB (the form lacking the COOH-terminal propeptide but still
containing the NH2-terminal one) when compared to antibodies directed
against the triple-helical part of type II collagen. These forms are the only
bands revealed in the cell layer of chondrocytes cultured for 36 hours after
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established by ELISA andWB. In addition, the Saos-2 cell linewas chosen to
test a possible labelling of other ﬁbrillar procollagens, mainly type I, V and
XI. In fact, this cell line is described to synthesize the (a1)I, (a2)I, (a1)V,
(a2)V, (a1)XI and (a2)XI, but no (a3)XI chains. No signal was detected on
WB of cellular extracts or conditioned media with anti-pNIIB52, whereas
antibodies to the collagen I, V and XI triple-helical parts revealed indeed
the presence of proforms of these collagens.
Conclusions: Anti-pNIIB52 antibodies allow a very sensitive and speciﬁc
detection of the procollagen IIB, the protein synthesized by mature chon-
drocytes. No cross-reactions with the IIA or with the major ﬁbrillar pro-
collagens synthesized by cells with an osteoblastic phenotype were
observed. These antibodies offer a new tool in basic aswell as in translational
research concerning cartilage differentiation, homeostasis and repair.
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INFLUENCE OF OXYGEN TENSION ON THE ANTI-INFLAMMATORY AND
CHONDROPROTECTIVE EFFECTS OF HEME OXYGENASE-1 IN HEALTHY
AND OSTEOARTHRITIC HUMAN CHONDROCYTES
M. Guillén 1,2, V. Clérigues 3, F. Gomar 4, C.L. Murphy 5, M. Alcaraz 3. 1Univ.
of Valencia, Burjasot, Valencia, Spain; 2CEU Cardenal Herrera Univ.,
Moncada, Spain; 3Univ. of Valencia, Burjasot, Valencia, Spain; 4Univ. of
Valencia, Valencia, SPAIN; 5Kennedy Inst. of Rheumatology, London, United
Kingdom
Purpose: Articular chondrocytes are adapted to live in conditions of low
O2. Such hypoxic conditions in the avascular cartilage play an important
role in extracellular matrix synthesis and survival of chondrocytes. In
previous work we have shown anti-inﬂammatory and chondroprotective
effects of heme oxygenase-1 (HO-1) on osteoarthritic (OA) condrocytes in
primary cultures in 20% O2. However, the inﬂuence of O2 tension on HO-1
function in healthy and OA chondrocytes remains unknown.
Methods: Human chondrocytes were obtained from healthy donors and
patients with diagnosis of advanced OA undergoing total knee joint
replacement. The chondrocyteswere isolated bydigestionwith collagenase
and used in primary culture. Healthy and OA chondrocyes were cultured in
20%or 1%O2 tension, and in 5%CO2. Cellswere stimulatedwith IL-1b (10 ng/
ml) for 48h. HO-1 was induced by incubation with 10 mM cobalt proto-
porphyrin IX (CoPP). Protein expression was assessed by Western blot,
ELISA and immunocytochemistry. Nitrite production and matrix metal-
loproteinase (MMP) activity were evaluated by ﬂuorometric methods. HO-
1 gene silencing was achieved by using a gene-speciﬁc siRNA.
Results: HO-1 proteinwas expressed in both healthy and OA chondrocytes
in hypoxia (1% O2) and normoxia (20% O2). IL-1b down-regulated HO-1
expression in all conditions whereas CoPP treatment counteracted this
effect. CoPP treatment was able to reduce the levels of TNFa and MMP
activity after IL-1b stimulation. CoPP also decreased the production of
nitrite induced by IL-1b in healthy and OA cells at both O2 concentrations.
This effect was accompanied by a reduction in iNOS expression at 24h. In
hypoxic conditions HIF-2a and SOX9 expression was decreased by IL-1b in
both healthy and OA chondrocytes. However, HO-1 induction was able to
reverse this effect and prevented the decrease in type collagen II. In
addition, IL-1b induced HIF-1a expression irrespective of O2 tension
whereas HO-1 induction by CoPP down-regulated HIF-1a expression in OA
chondrocytes only.
Conclusions: HO-1 induction in primary chondrocytes cultured in hypoxic
conditions resulted in stronger anti-inﬂammatory and chondroprotective
effects compared with normoxia. These results suggest that HO-1 could be
a physiologically important chondroprotective factor.
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HUMAN OSTEOARTHRITIS SYNOVIUM CONTAINS AN ALTERNATIVELY
SPLICED TRANSCRIPT OF ADAMTS4
S. Wainwright 1, J. Bondeson 2, C. Hughes 1, B. Caterson 1. 1Cardiff Sch. of
BioSci.s, Cardiff, United Kingdom; 2Dept of Rheumatology, Cardiff Univ.,
Cardiff, United Kingdom
Purpose: The characterization of an alternatively spliced transcript of the
ADAMTS4 aggrecanase.Methods: In human OA synovial cell cultures, RT-PCRwas performed using
oligonucleotide primers designed to amplify across the exon 8/9 region of
human ADAMTS4. The PCR products were puriﬁed using a QIAquick
puriﬁcation kit (Qiagen) and sequenced using in house facilities. A pCEP4
(Invitrogen) mammalian expression vector containing ADAMTS4 plus
a FLAG epitope was mutated using the QuikChange II site directed muta-
genesis kit (Stratagene) to contain the ADAMTS4 splice variant plus a FLAG
epitope. The recombinant proteins were puriﬁed from HEK293 transfected
cells using Anti-FLAG M2 afﬁnity gel (Sigma). Polyclonal antibodies were
raised against synthetic peptides representing sequences within the
C-terminal region of the splice variant of ADAMTS4 and the raised anti-
bodies were characterized using the recombinant splice variant of
ADAMTS4. The antibodies were used in immunohistochemical analysis of
human osteoarthritic synovium. The proteolysis of aggrecan and other
proteoglycans by the recombinant spice variant of ADAMTS4 was
investigated.
Results: The degradation of aggrecan is mainly mediated by the aggreca-
nases, of which ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2)
are the best known. We here characterize an alternative splice variant of
ADAMTS4.
RT-PCR performed as described above resulted in the ampliﬁcation of
normal ADAMTS4, and also a smaller product missing 161 base pairs from
the 5’ end of exon 9, the result of alternative splicing in which exon 8 joins
to a cryptic 3’ splice site within exon 9. The protein produced by this
alternative splicing would lack the spacer domain and have a C-terminus
lacking any homologies with the normal ADAMTS4 spacer domain. The
alternatively spliced transcript of ADAMTS4 was found in cultured OA
synovial cells and in freshly digested OA synovium, but not in human brain,
cervix or lung, or in normal bovine synovium. The protein synthesized
from this alternatively spliced transcript of ADAMTS4 would lose functions
dependent on its spacer domain, like substrate and matrix binding, and
inhibition through ﬁbronectin. Removal of the spacer domain from
ADAMTS4 has been reported to increase its ability to cleave aggrecan at the
Glu373-Ala374 bond, and it may well be that the alternatively spliced
transcript produces a protein that is secreted in a more active form.
HEK293 cells transfected with a pCEP4 vector containing the cDNA
sequence of the splice variant of ADAMTS4 produced the corresponding
protein in both the pro and active form. This protein could be found in the
media, but mostly associated with the cells, as conﬁrmed using antibodies
speciﬁc for the splice variant that were produced using synthetic peptides.
Immunohistochemical analysis of osteoarthritic synovium using these
antibodies showed staining of cells within the synovium. Proteins puriﬁed
by immunoprecipitation by Anti-FLAGM2 afﬁnity gel from transfected and
untransfected HEK293 cells were analysed using the ANASpec SensoLyte
520 Aggrecanase I assay kit. The splice variant had aggrecanase activity
comparable to a commercially available ADAMTS4. The splice variant
cleaved aggrecan at the G1u373-A1a374 site, as assessed by the neoepitope
monoclonal antibody BC3, with activity comparable to ADAMTS4.
Conclusions: ADAMTS4 is regulated at multiple levels through control of
gene expression, mRNA splicing and protein processing, as well as the
expression of naturally occurring inhibitors. We here describe the char-
acteristics of the ﬁrst known splice variant of ADAMTS4. This alternative
splice transcript of ADAMTS4 is expressed as a protein in vivo and can be
found in the synovium. It can be speculated that the changes in the
C-terminal domain of the protein resulting from this alternatively spliced
transcript would have changes in its substrate speciﬁcity. The protein
produced by the alternative spliced transcript of ADAMTS4 has aggreca-
nase activity, and the release of low levels of this fully active variant of
ADAMTS4 might be a factor in the slow process of superﬁcial zone
aggrecan loss in osteoarthritis.
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ANGIOPOIETIN-LIKE 4 PROMOTES TERMINAL CHONDROGENIC
DIFFERENTIATION
M. Mathieu 1,2, P. Chuchana 1,2, M. Iampietro 1,2, D. Noël 1,2,
C. Jorgensen 1,2. 1 Inserm U844, Montpellier, France; 2Université
Montpellier 1, Montpellier, France
Purpose: Mesenchymal stem cells (MSCs) are an attractive cell source for
cartilage tissue engineering given their ability to differentiate into
